美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · CCCC近 30 天 2 則 · 第 1 / 1 頁
- C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
- Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
- C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
- C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
- C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
- C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?
- Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
- C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D
- C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
- C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
- Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight
- C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets
- C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
- C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Assessing Roche Holding (SWX:ROG) Valuation After New C4 Therapeutics Oncology Partnership
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。